Experts convened by the National Institutes of Health for a Consensus Development Conference on Diagnosing Gestational Diabetes Mellitus (GDM) have proposed maintaining the current 2-step approach to diagnosis rather than a 1-step process. The panel, comprising 15 experts and 19 speakers, met March 4-9 in Bethesda to examine a report prepared through the Agency for Healthcare Research and Quality’s Evidence-based Practice Centers program. The assessment was sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Office of Disease Prevention.
Experts convened by the National Institutes of Health for a Consensus Development Conference on Diagnosing Gestational Diabetes Mellitus (GDM) have proposed maintaining the current 2-step approach to diagnosis rather than a 1-step process. The panel, comprising 15 experts and 19 speakers, met March 4-9 in Bethesda to examine a report prepared through the Agency for Healthcare Research and Quality’s Evidence-based Practice Centers program. The assessment was sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Office of Disease Prevention.
The 1-step approach to diagnosing GDM, a determination made based on 1 abnormal value, was proposed by the International Association of Diabetes and Pregnancy Study Groups (IADPSG). Currently a 2-step approach is used in the United States: a challenge test followed by a tolerance test, if needed. That approach is recommended by the American College of Obstetricians and Gynecologists.
The NIH panel noted that “despite the near uniformity of current practice in the United States, a number of controversies remain: the value of routine screening, the most appropriate method and glycemic thresholds for diagnosis, and the effects of treatment on the short- and long-term outcomes for women and their children.”
After examining the evidence, the NIH panel determined that the evidence is insufficient to adopt a 1-step approach. In its draft statement of March 6, the panel pointed out that the IADPSG 1-step strategy “would increase the number of women labeled as GDM two- to threefold and could increase personal and societal costs.” A diagnosis of GDM is inconvenient and anxiety-provoking as well as costly, they note in the report, and would result in a greatly increased workload (approximately 30%) for doctors, dieticians, and diabetes educators who work with women with GDM.
Evidence also exists, the panel noted, that labeling more women as having GDM may increase the incidence of cesarean delivery and prenatal testing.
Rising endometriosis rates linked to increased pregnancy complications
May 19th 2024A new study presented at the 2024 ACOG meeting reveals a significant rise in endometriosis among pregnant women over the past 20 years, linking the condition to increased obstetric and neonatal complications.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Impact of antiepileptic medications and sex hormones on maternal and child outcomes in epilepsy
May 16th 2024Paula Emanuela Voinescu, MD, PhD, director of the Women's Epilepsy Program at Brigham and Women's Hospital, talked about the influence of sex hormones on maternal outcomes in pregnant women with epilepsy treated with antiseizure medication.
Read More
Echogenic Mass identified as key predictor for retained products of conception
May 13th 2024Discover how recent findings highlight the significance of echogenic masses in accurately diagnosing post-pregnancy complications, shedding light on effective management strategies and reducing the need for invasive interventions.
Read More